Opinion|Videos|March 21, 2025
Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond
Panelists discuss how MARIPOSA-2 (Popat S, et al, ESMO 2024) and the September 2024 FDA approval of amivantamab plus chemo as a second-line option highlight advances in non–small cell lung cancer (NSCLC) treatment. Strategies involve sequencing with emerging therapies like HERTHENA-Lung01, addressing resistance, and central nervous system (CNS) metastases. The complete response letter (CRL) for HER3-DXd and the shift in biologics license application (BLA) status for Dato-DXd from TROPION-Lung05 (Lisberg A, et al, ASCO 2024) will shape clinical practices and resistance management moving forward.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on MARIPOSA-2 (Popat S, et al. ESMO 2024. Abs LBA54)and the recent FDA approval (September 2024) of combination amivantamab plus chemo as a second-line treatment option.
- How are you integrating the MARIPOSA-2 regimen into your clinical practice, and how do you sequence it with other available therapies?
- If you use MARIPOSA up front, what is your strategy in the second-line setting?
- How do emerging data from the HERTHENA-Lung01 study (Johnson M, et al. ESMO 2023. Abs 1319MO) inform your approach to managing treatment resistance management and CNS metastases?
- How might the recent CRL for HER3-DXd impact clinical practice over the next year?
- What are your perceptions of the latest data from TROPION-Lung05 and the recent shift in BLA status for Dato-DXd?(Lisberg A, et al. ASCO 2024. Abs 8593)
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5